Skip to content
etf.net

Launched

Amplify Weight Loss Drug & Treatment ETF

THNRNYSE ArcaC

$24.04−0.39 (−1.61%)

As of Oct 13, 2026, 3:58 PM

C43/ 100

Rank 7 of 9 in Pharma & Therapeutics

C43/100Rank 7 of 9inPharma & Therapeutics
Intraday session: down, 78 prints from 24.43 to 24.04. Range 24.04 to 24.44. Use the arrow keys to read each point.24.1024.2024.3010 AM12 PM2 PM4 PM
Expense ratio
0.59%
Fund size
$6M
1Y total return
+4.1%
Yield · Last 12 months
1.69%
Holdings
22
Avg volume · 30D
0M sh
NAV per share
$24.48
52W range
low $22.89high $27.94
Launched

The ETF.net THNR Grade

C

Score 43 out of 100

Category
Pharma & Therapeutics⁠
Rank
7 of 9
Six-pillar profile for THNR. Scores out of 100: Cost 41, Risk 35, Mission 65, Tradability 17, Holdings 65, Durability 18. Strongest: Mission (65). Weakest: Tradability (17). Leans toward Mission and Holdings.

Score 43 of 100 falls in the C band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    C41 out of 100
    Rank 5 of 9

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    B65 out of 100
    Rank 5 of 6

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    D35 out of 100
    Rank 7 of 9

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    F17 out of 100
    Rank 9 of 9

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    B65 out of 100
    Rank 4 of 9

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    F18 out of 100
    Rank 9 of 9

Our read on THNR

ETF.net Research

CThe GLP-1 trade in one ticker. THNR follows a global index of weight-loss drug developers plus the telehealth and treatment companies the index counts as economic beneficiaries, not just the obvious pharma giants.

Stated mandate

The fund provides access to global companies involved in weight-loss drug development or expected to benefit economically from increased use of these treatments, including drug manufacturers and telehealth providers.

Why people hold it

  1. 01Casts wider than the drugmakers: the mandate covers telehealth providers and other firms tied to rising use of weight-loss treatments.amplifyetfs.com
  2. 02Rules-based, not a hunch. It tracks VettaFi's Weight Loss Drug & Treatment Index (THINR), so the lineup changes by published methodology.
  3. 03Global by design, so European drugmakers count as much as US ones. Launched in 2024, as GLP-1 treatments moved from niche to headline.

Worth knowing

  1. 01The 0.59% expense ratio runs a touch above what global thematic funds typically charge.
  2. 02A small fund that trades lightly, so spreads can be wider than on big index funds. Limit orders are the usual tool here.
  3. 03One storyline, one drug class. Concentrated by construction, and distributions land annually or semiannually rather than as steady income.

THNR Holdings

As of Oct 13, 2026
Asset class
Stocks
Holdings
22
Top-10 weight
63%
Largest holding
LLY10.6%

Sectors

  • Health Care99.7%
  • Financials0.3%

Geography

  • United States55.23%
  • China13.16%
  • Denmark12.37%
  • Switzerland5.40%
  • United Kingdom5.40%
  • Japan4.87%
  • South Korea3.57%

Developed 63% · Emerging 37% of the foreign sleeve

The fund’s holdings, weight-ordered — page 1 of 2.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001LLYEli Lilly & Co10.60%503$595K583
002NVONovo Nordisk A/S8.82%12,835$495K33
003AMGNAmgen Inc5.86%788$329K491
004ABBVAbbVie Inc5.75%1,149$323K522
005PFEPfizer Inc5.51%10,896$309K378
006ROP.SWRoche Holding AG5.44%708$306K199
007GILDGilead Sciences Inc5.42%2,024$304K492
0081093.HKCSPC Pharmaceutical Group Ltd5.37%262,000$301K80
009AZNAstraZeneca PLC5.33%1,888$299K72
010MRKMerck & Co Inc5.25%2,025$295K515
011REGNRegeneron Pharmaceuticals Inc5.16%380$290K411
0121801.HKInnovent Biologics Inc5.12%24,500$288K88
0134519.TChugai Pharmaceutical Co Ltd4.73%7,000$265K134
014VKTXViking Therapeutics Inc4.60%9,118$258K92
015ARWRArrowhead Pharmaceuticals Inc3.83%3,541$215K144

Showing 1–15 of 22 holdings

THNR Performance

Launched May 21, 2024

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.Not enough history yet.Not enough history yet.
THNR$10,405
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$12,044
Oct 10, 2025 to Oct 12, 2026. THNR $10,405. SPY $12,044. Use the arrow keys to read each point.$9,419$10,837$12,255Oct 2025Apr 2026Oct 2026

Oct 10, 2025 – Oct 12, 2026

Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for THNR. Periods over one year show the average yearly return.
PeriodTHNR
Year to date−3.1%
1 month−4.5%
3 months−5.8%
1 year+4.1%
3 yearsFund is under 3 years oldper year—
5 yearsFund is under 5 years oldper year—
10 yearsFund is under 10 years oldper year—

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for THNR
YearReturn barTHNR
2026 YTD−3.1%
2025+13.7%
2024−10.4%

Since listing, May 21, 2024

THNR in the news

Filtered to THNR · Pharma & Therapeutics

THNR Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 12, 2026.
1.69%Last 12 months
Payout per share
$0.41Last 12 months
Last payment
$0.41 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Irregular

Distribution history

2024–2026

One bar per payment. 2 payments from 2024 to 2026 YTD. Dec 30, 2024 $0.22; Dec 30, 2025 $0.41. Use the arrow keys to read each point.202420252026YTD
Ex-datePay dateAmount per share
Dec 30, 2025Dec 31, 2025$0.41
Dec 30, 2024Dec 31, 2024$0.22

THNR Risk

How much the fund’s monthly returns vary, scaled to a year.
15.2%
Annualised · 28 months to Sep 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
−0.15
vs 3-month T-bills · 28 months to Sep 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−32.5%
28 months · trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.43
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

THNR Cost

Expense ratio0.59%
  • The middle half of Pharma & Therapeutics funds
  • Median 0.58%

5 of the 9 Pharma & Therapeutics funds charge less.

THNR costs $59.00 a year on $10,000. The median Pharma & Therapeutics fund costs $58.00.

Other funds in Pharma & Therapeutics

See others